The efficacy of EZH2 inhibition in various preclinical cancer models, and initially conducted with 3‐Deazaneplanocin A (DZNep)25 provided the rationale for evaluating Tazemetostat, a selective EZH2 inhibitor, in patients with relapsed/refractory lymphomas or various solid tumors.26 This evidence concerns the gene EZH2 and lymphoma.